There is a strong evidence demonstrating that decreased expression of Fas may protect transformed cells from elimination by anti-tumor immune responses, but heightened expression of FasL may increase the ability of tumor cells to counterattack the immune system by killing Fas sensitive lymphocytes and therefore contribute to lung cancer development [146,147,148,149,150]. The gene discussed is FAS; the disease is neoplasm.